Icelanders, whose unusually low genetic variability makes them ideal for
studies on the origin of diseases, have agreed to reveal the secrets of their
genes to pharmaceuticals company Hoffmann-La Roche. The deal, worth $200
million, gives the company and its partner—deCode Genetics of
Reykjavik—exclusive rights to develop drugs from the genetic data of
Iceland’s population. In return, Icelanders will receive any resulting medicines
free.
More from Â鶹´«Ã½
Explore the latest news, articles and features
Popular articles
Trending Â鶹´«Ã½ articles
1
How autoimmune conditions can unexpectedly drive mental illness
2
Exclusive report: Inside Chernobyl, 40 years after nuclear disaster
3
Why is it so hard to change your mind?
4
Largest ever map of universe captures 47 million galaxies and quasars
5
We're solving the fundamental mystery of how reality is glued together
6
You can now buy a DIY quantum computer
7
Neanderthal infants were enormous compared with modern humans
8
Electric vehicle owners could earn thousands by supporting power grid
9
The biggest threat to Chernobyl is no longer radiation
10
The surprising origins of Britain's Bronze Age immigrants revealed
